Combs Stephanie E
Department of Radiation Oncology, University Hospital of Heidelberg, Im Neuenheimer Feld 400, Heidelberg 69120, Germany.
Recent Results Cancer Res. 2009;171:125-40. doi: 10.1007/978-3-540-31206-2_7.
Radiation therapy is a main pillar in the multimodal treatment of gliomas. However, application of radiation has to be adapted to the distinct characteristics of the various glioma subtypes, with respect to dosing, time-point of irradiation, choice of treatment technique, and more recently, of radiation quality.Treatment of low-grade gliomas has been characterized by much controversy, which is still ongoing. For anaplastic gliomas, addition of chemotherapy to radiation alone is currently being discussed and is evaluated in prospective trials. For glioblastomas, a change in treatment paradigm has taken place with the alkylating agent temozolomide, which could increase survival significantly for the first time in many centuries. Moreover, the first steps toward pretreatment stratification have been established by defining the role of MGMT-promotor methylation for treatment response and outcome.Over the last few years, particle therapy with protons and carbon ions has become available. These new radiation qualities now offer promising treatment alternatives that will be evaluated within clinical studies in the near future and have the potential to further improve outcome in patients with gliomas.
放射治疗是胶质瘤多模式治疗的主要支柱。然而,放射治疗的应用必须根据不同胶质瘤亚型的独特特征进行调整,包括剂量、照射时间点、治疗技术的选择,以及最近的放射质量。低级别胶质瘤的治疗一直存在很大争议,目前仍在继续。对于间变性胶质瘤,目前正在讨论在单纯放疗基础上加用化疗,并在前瞻性试验中进行评估。对于胶质母细胞瘤,随着烷化剂替莫唑胺的出现,治疗模式发生了改变,这在许多世纪以来首次显著提高了生存率。此外,通过确定MGMT启动子甲基化对治疗反应和结果的作用,已经迈出了预处理分层的第一步。在过去几年中,质子和碳离子粒子治疗已经可用。这些新的放射质量现在提供了有前景的治疗选择,将在不久的将来在临床研究中进行评估,并有可能进一步改善胶质瘤患者的治疗结果。